May New Products and Industry News
- 0 Comments
- 3192 reads
Spiracur is thrilled that Highmark has elected to provide coverage for the wound care system as more payers continue to offer coverage for the device, the multitude of patients suffering from chronic wounds will have better access to an effective system.
Visit www.spiracur.com for more information.
NovaBay Pharmaceuticals Spotlights Positive Results From NeutroPhase Study
NovaBay Pharmaceuticals Inc (Emeryville, CA), is in the process of developing its anti-infective Aganocide® compounds for the local non-systemic treatment and prevention of antibiotic-resistant infections, presented a poster on the efficacy of NeutroPhase® solution (NVC-101) with the hydrophobic mesh Sorbact® in healing chronic nonhealing wounds at the recent 24th Annual Symposium on Advanced Wound Care and Wound Healing Society Meeting (SAWC/WHS) in Dallas, TX.
The poster, NeutroPhase® with Sorbact® Dramatically Enhances the Speed of Wound Healing, was written by researchers from the company and San Francisco Center for Advanced Wound Care at the Seton Medical Center (Daly City, CA). The poster reported on multiple case studies in the clinic in which a combination of 0.01% NeutroPhase with Sorbact as a wound mesh dressing capable of reducing maceration of adjacent skin and binding and inactivating pathogenic microorganisms, in conjunction with negative pressure wound therapy administered to 26 patients with chronic nonhealing wounds. The researchers demonstrated that the solution was capable of destroying biofilm in the wounds without damaging the surrounding tissues and was an effective topical antimicrobial that improved wound healing. Moreover, the hydrophobic mesh was found to help reduce tissue maceration. The company has two FDA 510(k) clearances for the solution and has begun moving forward toward larger scale manufacturing and eventual marketing by its Hospital Business Unit.
Visit www.novabaypharma.com for more information.